Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 41

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 41
---
 performance against our achievement of the key objectives and goals set forth in our annual business plan, which we refer to as our Corporate Objectives. The achievement of specified financial measures, such as annual operating income or revenue growth targets, are also considered to be important measures as a result of the growth and maturity of our company and our emergence as a long term, sustainably profitable business. In evaluating the overall performance of the Company, the Compensation Committee takes into account our strategic focus, which is to develop and commercialize products for the treatment of central nervous system (CNS) diseases. This strategy is anchored around the continued growth of our current commercial products and selective investments in our research and development pipeline, in-licensed technology and technology platforms which are designed to realize long-term growth for our Company. The strategy is also based on appropriate acquisitions of corporate assets. At the beginning of 2024, the CEO recommended, and the Compensation Committee and Board of Directors approved and assigned weights to certain Corporate Objectives for 2024 covering various key projects and financial goals including the following: • SPN-812 • Submit a specific filing to the Food and Drug Administration (“FDA”) for approval • Complete a specified study for a development project • Enroll 50% of patients in a specified study • SPN-817 • Topline data for Phase 2a study • Initiate Phase 2b study • SPN-820/821 • Complete Phase 2a study and report results • Complete enrollment in Phase 2b study • Complete a specified manufacturing objective • SPN-830 • Obtain FDA approval • Launch product

26

• SPN-840 • Complete requirement for supplemental new drug application • Financials • Achieve specific gross or net revenue objectives • Achieve adjusted EBITDA objective • R&D Discovery Program • Complete a specified pharmacology evaluation • File investigational new drug application for first-in-human study • Complete a specified manufacturing goal for first-in-human study • Initiate first-in-human study The cash bonus program has various payout levels depending on the Company’s performance measured against the Corporate Objectives. The payout of cash bonuses is primarily determined by the achievement of Corporate Objectives. For example, if 90% of our Corporate Objectives are achieved, 90% of the amount of each NEO’s cash bonus target attributable to the Corporate Objectives will be funded. The Board of Directors, based on the recommendation of the Compensation Committee and at its discretion, may adjust the payout levels. For 2024, the Corporate Objectives achievement level was